Balt is pleased to announce the publication of STEM trial results in the New England Journal of Medicine (NEJM).
The study demonstrated that among patients with symptomatic chronic subdural hematoma (cSDH), embolization using Balt’s SQUID TM liquid embolic resulted in a lower risk of treatment failure than standard treatment alone.
STEM is the first randomized prospective Investigational Device Exemption (IDE) trial investigating embolization for the treatment of this disease.
Need more information? We are here to help.
